Kornimate/medical-research-clean huggingface dataset:
calcium channel splice variant expression in cardiovascular disease and aging

Conditions: Atherosclerosis

Summary: the purpose of this study is to learn what changes in blood vessel contraction may occur as a result of a disease of the vessel that requires surgery. the study will examine the calcium channels present in the vessels being operated on, and the genes that may alter blood vessel function. possible variation in these genes may change the kind of calcium channels present in blood vessels.

the goal of this study is to learn more about how blood vessels function and the mechanism that causes them to contract. the study will investigate the natural history of diseased blood vessel tissue and the calcium channels in the muscle part of the blood vessel. the study will also examine how genetics influences cardiovascular disease and its causes and treatments. patients scheduled for vascular surgery will be approached to participate in this study. during surgery, tissue fragments of diseased and marginal tissue will be obtained. a blood sample will be obtained at either the time of surgery or consent and genomic dna will be extracted.

Eligibility criteria:
inclusion criteria: * ages 21 and older * scheduled for vascular surgery exclusion criteria: * unwillingness to be subjected to diagnostic and/or therapeutic procedures that are deemed not necessary for clinical management * volunteers deemed too fragile to participate in the study by the principal investigator (pi) or the attending physician * inability to obtain informed consent from either the volunteer or the responsible party (durable power of attorney \[dpa\]) for the volunteer, with the volunteer's assent

Keywords: vascular surgery vascular aging arterial aging surgical tissue aging
multicentre 2x2 factorial randomised study comparing tirofiban versus abciximab and ses versus bms in ami

Conditions: Myocardial Infarction

Summary: the purpose of this study is to determine which from the four combinations tirofiban+sirolimus eluting stent (ses), tirofiban+bare metal stent (bms), abciximab+ses, abciximab+bms is the possible gold standard treatment for st-segment elevation myocardial infarction in terms of efficacy and cost-efficacy.

the combination abciximab plus bare metal stent (bms) is currently considered the standard therapy for ami. the use of sirolimus eluting stent (ses) is related to a reduction of the need for urgent target vessel revascularization (tvr). with current acquisition prices for abciximab and ses, replacing abciximab with tirofiban, administered as a single high-dose bolus (shdb) regimen, is a promising strategy that would preserve financial resources. in a recent study the combination tirofiban and ses resulted to be associated to an overall lower major adverse cardiovascular events (mace) rate with respect to the abciximab plus bms. however, since no conclusion can be drawn yet regarding the relative contribution of a specific gp iib/iiia inhibitor or a stent type with respect to the other, the combination of abciximab and ses may be associated to an even lower event rate with respect to shdb tirofiban and ses, thus offsetting the higher initial cost. comparison(s): four strategies (shdb tirofiban + bms, shdb tirofiban + ses, abciximab + bms, abciximab + ses) are compared to determine the possible gold standard treatment for st-segment elevation myocardial infarction in terms of efficacy and cost-efficacy.

Eligibility criteria:
inclusion criteria: * st segment elevation myocardial infarction * schedule for primary percutaneous coronary intervention * informed consent exclusion criteria: * administration of fibrinolytic or any gp iib/iiia inhibitors for the treatment of current acute myocardial infarction or within 1 month before it * history of bleeding diathesis or allergy to the studies drug * major surgery within 30 days * limited life expectancy, e.g. neoplasms, others * pregnancy

Keywords: myocardial infarction revascularization stent st segment elevation
robotic tcd ultrasound bubble study compared to transthoracic echocardiography for detection of right to left shunt

Conditions: Embolic Stroke of Undetermined Source; Transient Ischemic Attack; Right-To-Left Atrial Shunt; Patent Foramen Ovale

Summary: this study is a multi-center, prospective, single-arm, non-significant risk (nsr) device study in which up to 150 evaluable subjects with suspicion of embolic stroke of undetermined source (esus) will be evaluated with nb-is tcd and standard of care tte to screen for right to left shunt (rls) or patent foramen ovale (pfo). additionally, up to 150 evaluable subjects will be evaluated with nb-is tcd and standard of care tee.

the objectives of the study is to evaluate the shunt detection rate of the neuralbot investigational system (nb-is) tcd relative to standard of care diagnostic techniques (transthoracic echocardiography (tte), transesophageal echocardiography (tee), and standard transcranial doppler ultrasound (tcd) and to assess the safety, accuracy and usability of the nb-is device.

Eligibility criteria:
inclusion criteria tte main study: 1. subject 18 years of age and older. 2. subject presents with a clinical condition characterized by neurological signs and symptoms that, in the opinion of the investigator, include embolic stroke or transient ischemic attack (tia) in the differential diagnosis. 3. scheduled for a transthoracic echocardiograph (tte) study with agitated saline contrast (bubble study) per standard of care within ±30 days of informed consent. 4. subject is able to successfully perform a valsalva maneuver (vm). 5. subject or legally authorized representative has the ability to provide informed consent and comply with the protocol. exclusion criteria tte main study: 1. subject has undergone a right to left shunt (rls) or patent foramen ovale (pfo) closure. 2. female who is pregnant or lactating at time of admission 3. subjects who underwent partial or full craniotomy/craniectomy within the past 6 months. 4. subjects who have a physical limitation preventing tcd headset placement inclusion criteria tee sub-study (after first 150 subjects in main tte study enrolled): 1. subject 18 years of age and older. 2. subject presents with a clinical condition characterized by neurological signs and symptoms that, in the opinion of the investigator, include embolic stroke or tia in the differential diagnosis. 3. scheduled for a transesophageal echocardiograph (tee) study with agitated saline contrast (bubble study) per standard of care within ±30 days of informed consent. 4. subject is able to successfully perform a valsalva maneuver (vm). 5. subject or legally authorized representative has the ability to provide informed consent and comply with the protocol. exclusion criteria tee sub-study (after first 150 subjects in main tte study enrolled): 1. subject has undergone a right to left shunt (rls) or patent foramen ovale (pfo) closure. 2. female who is pregnant or lactating at time of admission 3. subjects who underwent partial or full craniotomy/craniectomy within the past 6 months. 4. subjects who have a physical limitation preventing tcd headset placement.
personalized prediction strategy for acute exacerbation of chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this is a 3 year longitudinal study to establish a personalized prediction and prevention system for acute exacerbation of chronic obstructive pulmonary disease（aecopd). data will be collected which contained with clinical, pathophysiology, etiology and immunology information of chronic obstructive pulmonary disease(copd) patients and analyzed by data mining combined with internet technology.


Eligibility criteria:
inclusion criteria: * patients was diagnosed as copd according to global initiative for chronic obstructive lung disease (gold) guidelines older than 40 years old. * a signed and dated written informed consent is obtained prior to participation. * able to comply with the requirements of the protocol and be available for study visits over 3 years. exclusion criteria: * a copd subject will not be eligible for inclusion in this study if any of the following criteria apply: * known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first ct scan), other than copd (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis) * known history of significant inflammatory disease, other than copd (e.g. rheumatoid arthritis and lupus) * known to be severely alpha-1-antitrypsin deficient * has experienced a moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) within the last 4 weeks * having undergone lung surgery (e.g. lung reduction, lung transplant) * have cancer or have had cancer in the 5 years prior to study entry * having received a blood transfusion in the 4 weeks prior to study start * inability to walk * taking part in a blinded drug study * having therapy with systemic corticosteroids at inclusion.
transversalis fascia plane block and rectus sheath block in renal transplantation donors

Conditions: Postoperative Pain

Summary: transversalis fascia plane block (tfpb) is a relatively new, easy-to-apply and safe regional anesthesia technique used to provide postoperative analgesia in various surgeries. it has been shown that tfpb and rectus sheath block (rsb) administration reduces opioid consumption and related side effects in patients undergoing surgery with general anesthesia. to our knowledge, there is no study examining tfpb in donor nephrectomy. the investigators aimed to prospectively examine the effect of tfpb and rsb on opioid consumption in postoperative period on donors who will undergo laparoscopic nephrectomy in renal transplantation surgery.


Eligibility criteria:
inclusion criteria: * donor patients scheduled for elective nephrectomy in renal transplantation surgery * american society of anesthesiologists (asa) i-ii * patients who are aged between 18-75 exclusion criteria: * skin infection at the block area * coagulation disorder and using anticoagulant drugs * end-stage organ and system failure * severe pulmonary and/or cardiovascular problems * substance addiction or known psychiatric or mental problems * chronic painkiller usage
combination chemotherapy for metastatic breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer


Eligibility criteria:
inclusion criteria: * you are female in the age of 18 to 75 years old. * you have been diagnosed with the metastatic breast cancer. * you have desire and an opportunity to visit your doctor in medical site, both during realization of the active treatment program, and within 24 months of medical follow up. * you must sign this informed consent form exclusion criteria: * you are pregnant or breastfeeding. * your laboratory parameters fall outside the limits, admitted by requirements of the present clinical study. * you have been diagnosed with serious concomitant or acute infectious disease. * you have used experimental medications within the last month.
impact on revascularization outcomes of ivus guided treatment of complex lesions and economic impact

Conditions: Atherosclerosis

Summary: intravascular ultrasound (ivus)-guided percutaneous coronary intervention (pci) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after pci. this is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. despite extensive literature supporting the use of ivus in pci, utilization remains low in the united states. an increasing number of high-risk or complex lesions are being treated with pci and we hypothesize that the impact of ivus in these complex lesions will be of increased importance in reducing clinical adverse events while remaining cost effective.

this is a prospective, single-blind clinical investigation randomizing subjects to ivus-guided coronary stent implantation vs. angiography-guided coronary stent implantation in a 1:1 ratio. the clinical investigation will be conducted at approximately 120 centers in the us, canada, and europe. approximately 2,500-3,100 randomized subjects and up to 3 roll-in subjects per site will be enrolled in this study. subjects participating in this clinical investigation will be followed for 2 years. the expected duration of enrollment is approximately 2.5 years. the total duration of the clinical investigation is expected to be approximately 4.5 years.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years at screening * pci with stent implantation involving a high risk or complex lesion defined as involving at least one of the following characteristics: * chronic total occlusion * in-stent restenosis * severe coronary artery calcification * long lesion (≥ 28 mm in length) * bifurcation lesion (any medina class that involves main branch disease with a side branch ≥2.0 mm) * stable angina, unstable angina, or non-st elevation myocardial infarction (nstemi), undergoing pci of a single or multivessel coronary artery stenosis * pci performed with either angiography alone, or ivus guidance used exclusion criteria: * subjects with acute st elevation myocardial infarction (stemi), or cardiogenic shock * use of fibrinolytic therapy within 24 hours of pci * planned revascularization of a target vessel as a staged procedure * stent thrombosis * use of optical coherence tomography (oct) during the index procedure
differences in evoked intracellular interferon signaling pathways using single cell phosphoprotein profiling

Conditions: Hepatitis C

Summary: purpose: the purpose of this exploratory study is to evaluate phosphoprotein profiling to determine differences in the intracellular actions of interferon or interferon stimulated genes among people with different treatment outcomes to interferon based therapy for hepatitis c (hcv). participants: patients with genotype 1 hcv who have had interferon based therapy at the university of north carolina (unc). procedures: thirty patients with varied responses to treatment will be given a single subcutaneous injection of interferon alpha 2b. prior to the injection and at 30 minutes, 1,2,4,6,12 and 20 hours after injection, blood will be drawn for analysis of phosphoprotein profiling and changes in serum cytokines.


Eligibility criteria:
inclusion criteria: to be eligible for this study, subjects must meet the following inclusion criteria: * willing and able to provide informed consent * males or females age 18 - 65 years * for women of childbearing potential, negative blood pregnancy test documented within the 24-hour period prior to ifn-α administration * history of genotype 1 hcv infection previously treated with peginterferon and ribavirin and with a virological response that can be determined from retrospective review of medical records * a washout period of \>12 weeks between the last dose of prescribed peginterferon and ribavirin and the screening visit exclusion criteria subjects with any of the following will not be eligible for participation: * neutrophil count \<1500 cells/mm3, hgb \<12 g/dl in women or 13 g/dl in men, or platelet count \<75,000 cells/mm3 at screening * serum creatinine level \>1.5 times the upper limit of normal at screening * poorly controlled psychiatric illness, as determined by the study physician, which can be exacerbated by interferon therapy * infection requiring antibiotics, symptomatic viral infection, inflammatory process requiring therapy, or allergic reactions in the week immediately preceding the inpatient study visit * use of medications that affect the immune system (e.g. glucocorticoids, chronic nsaids daily) in the week immediately preceding the inpatient study visit * history of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, psoriasis, rheumatoid arthritis) * women with ongoing pregnancy or breast-feeding * history or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease * history of a seizure disorder or current anticonvulsant use * history of major organ transplantation with an existing functional graft * history of thyroid disease poorly controlled on prescribed medications * history or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
the effect of hand and foot massage on fatigue in hemodialysis patients

Conditions: Hemodialysis Patients

Summary: hemodialysis patients face many problems related to disease and treatment, fatigue is stated as the most common of these problems. therefore, the aim of this study is to examine the effect of hand massage and foot massage on fatigue in hemodialysis patients.

in parallel with the recent technological advances in medicine, increasing the possibilities of diagnosis and treatment of diseases has increased the average life expectancy and the incidence of chronic diseases. chronic renal failure (crf), which is one of the increasing chronic diseases, has become an important public health problem due to its negative impact on quality of life both in the world and in our country, high morbidity, mortality and treatment costs. according to the joint report of the turkish ministry of health and turkish nephrology association; by the end of 2016, renal replacement therapy (rrt) applied total 74,475 patients (including pediatric patients), rrt is applied and while the most common form of treatment has been found to be hemodialysis treatment with 76.12%. unless a successful renal transplantation is performed, hemodialysis treatment required to be performed until the end of life and provides a longer life, but it also causes biological, psychological, social and economical problems arising from treatment. fatigue, which often related to problems with its biological dimension, reduces the quality of life by adversely negatively affecting individual's daily life activities.

Eligibility criteria:
inclusion criteria: * - taking hd therapy, in the dialysis unit of a public hospital in turkey, between october 19, 2018 - february 11, 2019, * agree to participate in the study with a written permission, * over the age of 18, * open to communication with complete orientation, * speaks and understands turkish * receiving hd treatment 3 times a week for 6 months and longer, * no loss of sensation, mass, fracture or ingrown toenail (onyxis), * in the lower extremities; without pathological and tumoral disease, phlesis, embolism and no bleeding disorder related to amputation, fracture, infection, wound, skin disease, muscle and bones, * patients with a standardized mini mental test (smmt) score of 24 or more, in patients older than 65 years, exclusion criteria: -

Keywords: nursing hemodialysis fatigue hand massage foot massage
dynamic contrast-enhanced magnetic resonance imaging analysis for prognosis of intracranial dissecting aneurysm with intramural hematoma after endovascular treatment

Conditions: Dissecting Aneurysm of Cerebral Artery

Summary: this study will evaluate the feasibility to predict the prognosis of ida with imh by dce-mri and provide theoretical basis for the prognosis and intervention of the disease.

intracranial dissecting aneurysm (ida) was a challenging disease and could result in stroke in young and middle-aged adults. intramural hematoma, one of the typical imaging findings of ida, can grow continuously in untreated ida. due to relatively high complication rate associated with surgical procedures, endovascular treatments have become the first-line therapy for such lesions. according to whether the parent artery was maintained, endovascular treatment was divided into deconstructive (proximal arterial occlusion and internal trapping) and reconstructive (stent implantation with or without coiling) techniques . however, recanalization of ida was a great challenge for endovascular treatment and influenced the prognosis of patients. the formation of an imh is a critical event in the progress of ida and ida may grow because of recurrent imh even after deconstructive endovascular treatment. increased imh size could result in severe compression symptoms or even death. at present, the mechanism of the continuous growth of intramural hematoma after endovascular treatment of ida is still unclear. some authors believe that the continuous hemorrhage of the vasa vasorum in the imh results in the continuous enlargement of the imh. however, this theory has not been proved by imaging in vivo. dynamic contrast-enhanced magnetic resonance imaging analysis for prognosis of intracranial dissecting aneurysm with intramural hematoma after endovascular treatment (demat) is a prospective trial designed to collect a large series of patients with idas treated endovascularly to predict the prognosis of ida with imh by dce-mri and provide theoretical basis for the prognosis and intervention of the disease.

Eligibility criteria:
inclusion criteria: adult patients (age 18-80 years) patients' ability to cooperate during the mri examination; patients who are were diagnosed with ida according to dsa and mri; expectation of adequate patient safety during these examinations; unequivocal evidence by mri (imh\>5 mm on the perpendicular plane to the long axis of the vessel) of ida; ida treated by the endovascular approach; patients' willingness to participate in the study. exclusion criteria: patients with pre-existing diagnoses of arteritis, fibromuscular dysplasia, iatrogenic aneurysms or pseudoaneurysms; extracranial dissecting aneurysms extended into the intracranial segment; patients with other diseases or poor general condition with expected survival of less than 2 year; the ida has already been treated by the endovascular treatment; patients lacking dce-mri follow up.

Keywords: contrast-enhanced magnetic resonance imaging intracranial dissecting aneurysm intramural hematoma prognosis
effects and safety of budesonide inhalation suspension via transnasal nebulization in nasal polyps

Conditions: Nasal Polyps

Summary: this randomized, double-blind, placebo-controlled clinical trial enrolled subjects with eosinophilic crswnp. subjects were randomized to receive either budesonide inhalation suspension or placebo for 14 days. visual analogue scales (vas）of nasal symptoms, endoscopic polyp scores and morning serum cortical levels were assessed pre- and post-treatment. polyp samples were evaluated for inflammatory cytokines, matrix metalloproteinases (mmps) and tissue inhibitors of metalloproteinases (timps) by immunoassay; collagen by histochemistry; and frequencies of different inflammatory t cell infiltration by flow cytometry. this study is undertaken to evaluate the efficacy of short-term prescription of budesonide inhalation suspension via transnasal nebulization by clinical and immunologic assessments. as outcome parameters for remodeling, differences in the expression of collagen and albumin were investigated before and after budesonide treatment. meanwhile, tgf-β, mmps and timps expression differences in nasal polyps were investigated to explore underlying mechanisms of tissue reconstitution.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic rhinosinusitis was made on the basis of symptoms of rhinosinusitis for at least 12 weeks, confirmed by abnormalities in all sinuses on computed tomography scan. * bilateral nasal polyps were present. * crswnp was defined as eosinophilic when percent of tissue eosinophils exceeded 10% of total infiltrating cells. * all patients had taken no steroids or antibiotics for at least 4 weeks before sample collection. exclusion criteria: * cystic fibrosis * pregnancy * serious or unstable concurrent disease * psychological disorder.

Keywords: nasal polyps remodeling inflammatory cells budesonide